National Institute on Drug Abuse; Notice of Closed Meeting, 20487 [E9-10099]

Download as PDF Federal Register / Vol. 74, No. 84 / Monday, May 4, 2009 / Notices collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Dated: April 29, 2009. Janean Chambers, Reports Clearance Officer. [FR Doc. E9–10133 Filed 5–1–09; 8:45 am] BILLING CODE 4184–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Organ Transplant Infection Detection and Prevention Program, Funding Opportunity Announcement (FOA) CK09–003, Initial Review tjames on PRODPC75 with NOTICES Time and Date: 12 p.m.–3 p.m., June 11, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘Organ Transplant Infection Detection and Prevention Program, FOA CK09–003.’’ Contact Person for More Information: Wendy Carr, PhD, CDC, 1600 Clifton Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone: (404) 498–2276. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. VerDate Nov<24>2008 15:26 May 01, 2009 Jkt 217001 Dated: April 24, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–10193 Filed 5–1–09; 8:45 am] Dated: April 24, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–10190 Filed 5–1–09; 8:45 am] BILLING CODE 4163–18–P BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institutes of Health Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of New Technology To Improve Delivery of Immunizations, Funding Opportunity Announcement (FOA) IP09–005 Initial Review; Development, Implementation and Evaluation of Strategies To Increase Vaccination of Adolescents Affiliated With a Medical Home, FOA IP09–006 Initial Review; Determine the Impact of Strategies To Vaccinate All Children for Influenza in a Practice Setting, FOA IP09–007, Initial Review In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. 20487 Time and Dates: 8 a.m.–5 p.m., May 21, 2009 (Closed). 8 a.m.–5 p.m., May 22, 2009 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of ‘‘Evaluation of New Technology to Improve Delivery of Immunizations, FOA IP09–005;’’ ‘‘Development, Implementation and Evaluation of Strategies to Increase Vaccination of Adolescents Affiliated with a Medical Home, FOA IP09–006;’’ ‘‘Determine the Impact of Strategies to Vaccinate all Children for Influenza in a Practice Setting, FOA IP09–007.’’ Contact Person for More Information: Wendy Carr, PhD, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, GA 30333, Telephone: (404) 498–2276. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDA. Date: June 1, 2009. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Intramural Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21224. Contact Person: Stephen J. Heishman, PhD, Research Psychologist, Clinical Pharmacology Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224. (410) 550–1547. (Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: April 27, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–10099 Filed 5–1–09; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\04MYN1.SGM 04MYN1

Agencies

[Federal Register Volume 74, Number 84 (Monday, May 4, 2009)]
[Notices]
[Page 20487]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-10099]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Board of Scientific Counselors, NIDA.
    The meeting will be closed to the public as indicated below in 
accordance with the provisions set forth in section 552b(c)(6), Title 5 
U.S.C., as amended for the review, discussion, and evaluation of 
individual intramural programs and projects conducted by the National 
Institute on Drug Abuse, including consideration of personnel 
qualifications and performance, and the competence of individual 
investigators, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: Board of Scientific Counselors, NIDA.
    Date: June 1, 2009.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate personal qualifications and 
performance, and competence of individual investigators.
    Place: Intramural Research Program, National Institute on Drug 
Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21224.
    Contact Person: Stephen J. Heishman, PhD, Research Psychologist, 
Clinical Pharmacology Branch, Intramural Research Program, National 
Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 
Nathan Shock Drive, Baltimore, MD 21224. (410) 550-1547.

(Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: April 27, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-10099 Filed 5-1-09; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.